Table 1.

Patient characteristics for anti-CTLA4 and anti-PD1 cohorts

Anti-PD1Anti-CTLA4
Patient characteristicsN (%)N (%)
Age, years
 <402 (5.3)3 (7.1)
 40–5511 (28.9)14 (33.3)
 56–7014 (36.8)18 (42.9)
 >7011 (28.9)7 (16.7)
Gender
 Male27 (71.1)23 (54.8)
 Female11 (28.9)19 (45.2)
PFS
 <3 months9 (23.7)13 (59.1)
 3–9 months11 (28.9)6 (27.3)
 >9 months18 (47.4)3 (13.6)
RECIST1.1 at ∼12 weeks
 CR1 (2.6)2 (4.8)
 PR11 (28.9)10 (23.8)
 SD12 (31.6)3 (7.1)
 PD14 (36.8)27 (64.3)
BRAF mutation status
 Wild-type27 (73.0)
 Mutated10 (27.0)
NRAS mutation status
 Wild-type21 (60.0)
 Mutated14 (40.0)
Previous treatments
 Chemotherapy3 (7.9)
 Targeted therapy2 (5.3)
 Immunotherapy (ipilimumab)28 (73.7)
 Radiotherapy4 (10.5)
 Interferon1 (2.6)
Lactate dehydrogenase (LDH/ULN)
 <120 (54.1)27 (67.5)
 ≥117 (45.9)13 (32.5)
S100
 <0.2 μg/L10 (27.8)
 ≥0.2 μg/L26 (72.2)
ANC
 <8 g/L35 (92.1)40 (95.2)
 ≥8 g/L3 (7.9)2 (4.8)
ALC
 <1.5 g/L25 (65.8)28 (66.7)
 ≥1.5 g/L13 (34.2)14 (33.3)
Leukocytes
 <9.6 g/L34 (89.5)
 ≥9.6 g/L4 (10.5)
Basophils
 <0.15 g/L20 (52.6)
 ≥0.15 g/L18 (47.4)
Eosinophils
 <0.7 g/L36 (94.7)
 ≥0.7 g/L2 (5.3)
  • NOTE: N, number of patients in each category. %, representation in percent for each category.